following a resubmission:
sodium zirconium cyclosilicate (Lokelma®) is accepted for restricted use within NHSScotland.
Indication under review: treatment of hyperkalaemia in adult patients.
SMC restriction: patients with hyperkalaemia (defined as a serum potassium of >6.0mmol/L) with chronic kidney disease (CKD) stage 3b to 5 and/or heart failure, who would otherwise need to down-titrate or discontinue their renin-angiotensin-aldosterone system inhibitor (RAASi) therapy to maintain a clinically acceptable serum potassium level (normokalaemia)
Sodium zirconium cyclosilicate, compared with placebo, reduced serum potassium in two and four-week studies in adults with hyperkalaemia. In an uncontrolled one-year study sodium zirconium cyclosilicate produced normal serum potassium in a proportion of adults with hyperkalaemia.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) delivering the cost-effectiveness results upon which the decision was based, or a PAS/list price that is equivalent or lower.
- Medicine name:
- sodium zirconium cyclosilicate (Lokelma)
- SMC ID:
For the treatment of hyperkalaemia (HK) in adult patients.
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Date advice published
- 07 September 2020